# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and maintains $7 price target.
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share. The company reported quarterly sales of $7.84 million...
The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for pho...
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(2.88) per share which missed the analyst consensus estimate of $(1.17)...